IP Library › Assignment 057730/0993
Patent Assignment
Reel/Frame 057730/0993

Assignment of Assignor's Interest

Recorded: 2021-10-07 Pages: 5
Assignor
PROMETHEUS BIOSCIENCES, INC.
Executed: 2021-09-30
Assignee
PROMETHEUS LABORATORIES INC.
9410 CARROLL PARK DRIVE, SAN DIEGO, CALIFORNIA, 92121
Covered Properties (25)
Methods of Quantifying Methotrexate Metabolites
Method for Direct Detection of Individual Methotrexate Metabolities
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
Methods of Predicting Methotrexate Efficacy and Toxicity
Methods of Quantifying Methotrexate Metabolites
Patent: 7,563,590 →
Application: 10/232,760 →
Publication: US 2004/0043441
Methods for Direct Detection of Individual Methotrexate Metabolites
Patent: 6,921,667 →
Application: 10/384,066 →
Publication: US 2004/0175834
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Patent: 7,582,282 →
Application: 10/927,904 →
Publication: US 2005/0112627
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
Patent: 7,695,908 →
Application: 11/152,128 →
Publication: US 2006/0057609
Methods of Predicting Methotrexate Efficacy and Toxicity
Application: 11/380,171 →
Publication: US 2006/0286571
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application: 12/191,286 →
Publication: US 2009/0197266
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application: 12/191,287 →
Publication: US 2009/0197267
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application: 12/191,290 →
Publication: US 2009/0197268
Methods of Predicting Methotrexate Efficacy and Toxicity
Application: 12/194,501 →
Publication: US 2010/0203507
Methods of Predicting Methotrexate Efficacy and Toxicity
Application: 12/194,503 →
Publication: US 2010/0203508
Methods of Quantifying Methotrexate Metabolites
Application: 12/484,148 →
Publication: US 2010/0159493
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
Application: 12/698,966 →
Publication: US 2010/0203539
Methods of Quantifying Methotrexate Metabolites
Application: 13/158,082 →
Publication: US 2011/0262948
Methods of Predicting Methotrexate Efficacy and Toxicity
Application: 13/709,558 →
Publication: US 2013/0143215
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application: 13/750,282 →
Publication: US 2013/0131072
Methods for optimizing clinical responsiveness to chemotherapy
Application: 60/514,423 →
Methods for optimizing clinical responsiveness to low-dose anti-folate therapy
Application: 60/560,752 →
Methods for predicting methotrexate polyglutamate levels using pharmacogenetics
Application: 60/580,141 →
Methods for evaluating risk associated with methotrexate therapy using pharmacogenetics
Application: 60/676,442 →
Methods for monitoring methotrexate therapy using pharmacogenomic and metabolite biomarkers
Application: 60/731,598 →
Related Assignments (14)
Other recorded transfers of the patents in this record — the chain of ownership.
Short-Form Patent Security Agreement Oct 15, 2013
From: EXAGEN DIAGNOSTICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031414/0660 →
Release of Security Interest Dec 29, 2015
From: BANK OF AMERICA, N.A.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 037378/0464 →
Release of Security Interest Sep 1, 2017
From: CYPRESS BIOSCIENCE INC.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043747/0382 →
Release of Security Interest Sep 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043784/0828 →
Security Interest Sep 11, 2017
From: EXAGEN DIAGNOSTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 043548/0228 →
Merger Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
Corrective Assignment to Correct the English Translation to Show the Full and Correct New Name in Section 51. Previously Recorded at Reel: 049391 Frame: 0756. Assignor(S) Hereby Confirms the Merger. Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
Assignment of Assignor's Interest Aug 26, 2019
From: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
To: PRECISION IBD, INC.
Reel/Frame 050166/0001 →
Change of Name Oct 17, 2019
From: PRECISION IBD, INC.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 050886/0942 →
Corrective Assignment to Correct the Patent Number 16062921 Previously Recorded on Reel 049391 Frame 0756. Assignor(S) Hereby Confirms the Patent Number Should Have Been 16062912. Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
Corrective Assignment to Correct the Patent Number 16062921 Previously Recorded on Reel 049391 Frame 0756. Assignor(S) Hereby Confirms the Patent Number Should Have Been 16062912. Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
Assignment of Assignor's Interest Nov 3, 2021
From: PROMETHEUS LABORATORIES INC.
To: EXAGEN INC.
Reel/Frame 058007/0978 →
Release of Security Interest Apr 25, 2025
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: EXAGEN INC.
Reel/Frame 070951/0040 →
Security Interest Apr 25, 2025
From: EXAGEN INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070952/0802 →